What does this research mean for the field?

PIK3CA is a major oncogenic driver across human malignancies, and targeting the PI3K pathway—particularly in combination with other targeted therapies or immunotherapy—represents a clinically actionable and evolving strategy in precision oncology. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To provide a comprehensive overview of the biological mechanisms, alteration landscape, and clinical targeting of the oncogenic PIK3CA catalytic subunit across human cancers.

August 30, 2026CancersOpen Access

PIK3CA in Cancer: Structure, Biology, Alterations, and Actionability

View Full Paper

Ask AI

Bookmark

Authors

AOAlessandro OttaianoIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale"CPCarmine PiconeUniversity of Molise MSMariachiara SantorsolaIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Discussion

Member takes

Implication

Narrative review uncovers PIK3CA alterations and targeted treatment strategies across human cancers, highlighting rational combination therapies to overcome drug resistance.

Key Points

To provide a comprehensive overview of the biological mechanisms, alteration landscape, and clinical targeting of the oncogenic PIK3CA catalytic subunit across human cancers.
Synthesized two decades of structural biology, cancer genomics, and translational oncology evidence regarding the PI3Kα complex and PIK3CA oncogenic activation.
Evaluated approved and experimental PI3K-targeted therapeutics, rational combination strategies, and precision oncology modalities across clinical trials and preclinical studies.
PIK3CA mutations drive tumorigenesis, metastasis, and therapy resistance while critically remodeling the immunosuppressive tumor microenvironment.
Clinical evidence validates combining PI3K inhibitors with endocrine therapy, CDK4/6 inhibitors, MAPK inhibitors, dual PI3K/mTOR blockers, and immune checkpoint inhibitors.
Implementation of integrated molecular profiling, liquid biopsies, and single-cell technologies offers necessary pathways to refine patient selection and overcome therapeutic resistance.

Cite This Study

Ottaiano et al. (2026) studied this question.

synapsesocial.com/papers/6a93f07a6c1a8fb52e79ca78 https://doi.org/10.3390/cancers18172798

View Full Paper

Ask AI

Bookmark

August 30, 2026CancersOpen Access

PIK3CA in Cancer: Structure, Biology, Alterations, and Actionability

View Full Paper

Ask AI

Bookmark

Authors

AOAlessandro OttaianoIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale"CPCarmine PiconeUniversity of Molise MSMariachiara SantorsolaIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Discussion

Member takes

Implication

Narrative review uncovers PIK3CA alterations and targeted treatment strategies across human cancers, highlighting rational combination therapies to overcome drug resistance.

Key Points

To provide a comprehensive overview of the biological mechanisms, alteration landscape, and clinical targeting of the oncogenic PIK3CA catalytic subunit across human cancers.
Synthesized two decades of structural biology, cancer genomics, and translational oncology evidence regarding the PI3Kα complex and PIK3CA oncogenic activation.
Evaluated approved and experimental PI3K-targeted therapeutics, rational combination strategies, and precision oncology modalities across clinical trials and preclinical studies.
PIK3CA mutations drive tumorigenesis, metastasis, and therapy resistance while critically remodeling the immunosuppressive tumor microenvironment.
Clinical evidence validates combining PI3K inhibitors with endocrine therapy, CDK4/6 inhibitors, MAPK inhibitors, dual PI3K/mTOR blockers, and immune checkpoint inhibitors.
Implementation of integrated molecular profiling, liquid biopsies, and single-cell technologies offers necessary pathways to refine patient selection and overcome therapeutic resistance.

Cite This Study

Ottaiano et al. (2026) studied this question.

synapsesocial.com/papers/6a93f07a6c1a8fb52e79ca78 https://doi.org/10.3390/cancers18172798

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark